Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: VIV; VIVXF

Life Sciences Firm Contracts with Philippines Distributor
News Update

Source:

This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product.

Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced in a news release it entered a contract wherein INPHILCO Inc. will become a key distribution partner, distributing OxC-beta™ Livestock in the Philippines. This follows the memorandum of understanding the two companies signed in December 2019.

Manila-based INPHILCO is a veterinary company that covers poultry, swine, aquaculture, pet and feed mill requirements for animal nutrition, animal health and raw materials for compound feeds.

Per the new arrangement, INPHILCO will have the exclusive right to sell Avivagen's OxC-beta Livestock both as a component of its premixes and as a standalone product. INPHILCO will purchase OxC-beta directly from Avivagen.

"INPHILCO brings a well-earned reputation for high-quality products and deep-rooted relationships with both large integrated feed producers and commercial farms to the table, which will set the stage for increased OxC-beta Livestock use for both swine and poultry in this very important region," Avivagen CEO Kym Anthony said in the release.

The feed market in the Philippines is growing rapidly. Annual feed production there in 2020 is an estimated 18.2 million metric tons, Avivagen noted.

[NLINSERT]

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.




Learn More about Which Online Broker is Right for You?

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe